MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase

Overview

Journal J Oncol

Specialty Oncology

Date 2021 Oct 4

PMID 34603447

Authors

Huilin Ou

Keda Chen

Hongcheng Wu

Affiliations

Soon will be listed here.

Abstract

Background: The Ron receptor tyrosine kinase (RON) can act as a protooncogene and may play a prominent role in the initiation and development of lung cancer. microRNAs (miRNA) are master regulators of gene expression through direct or indirect regulation, and impact all aspects of cell biology.

Methods: Nonsmall-cell lung cancer (NSCLC) samples and small-cell lung cancer (SCLC) were stratified based on RON expression to identify miRNA profiles associated with RON expression levels, differentially expressed miRNA regulated by RON were screened out, and their biological behavior was analyzed.

Results: miRNA expression was most significantly affected by cancer type, and we found 85 miRNAs that were significantly differentially expressed between NSCLC and SCLC. There were 46 miRNAs differentially expressed between high RON expressing NSCLC compared to low RON expressing NSCLC. Biological processes and pathways found to be significantly influenced by RON expression included epithelial-mesenchymal transition (EMT) and activation of the PI3K-Akt and MAPK signaling pathways.

Conclusions: These data may provide the basis for a novel strategy to characterize lung cancer by RON expression and microRNA genotyping.

References

Kim S, Lee K, Lee D, Lee J, Lim S, Joo Y . Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. Int J Oncol. 2019; 55(2):513-526. DOI: 10.3892/ijo.2019.4836. View

Pan Y, Wei L, Wu X, Huo F, Mou J, Pei D . MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5. Cell Death Dis. 2017; 8(10):e3155. PMC: 5680926. DOI: 10.1038/cddis.2017.561. View

Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M . MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. 2015; 6(36):38695-704. PMC: 4770730. DOI: 10.18632/oncotarget.5735. View

Tadano T, Kakuta Y, Hamada S, Shimodaira Y, Kuroha M, Kawakami Y . MicroRNA-320 family is downregulated in colorectal adenoma and affects tumor proliferation by targeting CDK6. World J Gastrointest Oncol. 2016; 8(7):532-42. PMC: 4942741. DOI: 10.4251/wjgo.v8.i7.532. View

Croce C, Calin G . miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6-7. DOI: 10.1016/j.cell.2005.06.036. View

Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y . Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 2012; 18(18):5144-53. DOI: 10.1158/1078-0432.CCR-12-0701. View

Ekhteraei-Tousi S, Mohammad-Soltani B, Sadeghizadeh M, Mowla S, Parsi S, Soleimani M . Inhibitory effect of hsa-miR-590-5p on cardiosphere-derived stem cells differentiation through downregulation of TGFB signaling. J Cell Biochem. 2014; 116(1):179-91. DOI: 10.1002/jcb.24957. View

Ding D, Li C, Zhao T, Li D, Yang L, Zhang B . LncRNA H19/miR-29b-3p/PGRN Axis Promoted Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Acting on Wnt Signaling. Mol Cells. 2018; 41(5):423-435. PMC: 5974619. DOI: 10.14348/molcells.2018.2258. View

Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu X . miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression. Oncotarget. 2016; 7(30):48547-48561. PMC: 5217037. DOI: 10.18632/oncotarget.10423. View

10.

Daugaard I, Sanders K, Idica A, Vittayarukskul K, Hamdorf M, Krog J . miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. 2017; 6(7):e366. PMC: 5541717. DOI: 10.1038/oncsis.2017.66. View

11.

Abd-Aziz N, Kamaruzman N, Poh C . Development of MicroRNAs as Potential Therapeutics against Cancer. J Oncol. 2020; 2020:8029721. PMC: 7378626. DOI: 10.1155/2020/8029721. View

12.

Zeng X, Huang C, Senavirathna L, Wang P, Liu L . miR-27b inhibits fibroblast activation via targeting TGFβ signaling pathway. BMC Cell Biol. 2017; 18(1):9. PMC: 5240426. DOI: 10.1186/s12860-016-0123-7. View

13.

Cooks T, Pateras I, Jenkins L, Patel K, Robles A, Morris J . Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018; 9(1):771. PMC: 5823939. DOI: 10.1038/s41467-018-03224-w. View

14.

Bourn J, Ruiz-Torres S, Hunt B, Benight N, Waltz S . Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. Cancer Lett. 2021; 503:75-90. PMC: 7981256. DOI: 10.1016/j.canlet.2021.01.019. View

15.

Weng T, Yao M, Xu X, Hu C, Yao S, Liu Y . RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer. Cancer Res Treat. 2020; 52(3):973-986. PMC: 7373856. DOI: 10.4143/crt.2019.726. View

16.

Chen Y, Zhou Y, Fu L, Wang D, Wang M . Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis. 2002; 23(11):1811-9. DOI: 10.1093/carcin/23.11.1811. View

17.

Zhou D, Zhang L, Sun W, Guan W, Lin Q, Ren W . Cytidine monophosphate kinase is inhibited by the TGF-β signalling pathway through the upregulation of miR-130b-3p in human epithelial ovarian cancer. Cell Signal. 2017; 35:197-207. DOI: 10.1016/j.cellsig.2017.04.009. View

18.

Shui Y, Yu X, Duan R, Bao Q, Wu J, Yuan H . miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. Gene. 2017; 609:80-87. DOI: 10.1016/j.gene.2017.01.036. View

19.

Pao W, Girard N . New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2):175-80. DOI: 10.1016/S1470-2045(10)70087-5. View

20.

Wolf J, Seto T, Han J, Reguart N, Garon E, Groen H . Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(10):944-957. DOI: 10.1056/NEJMoa2002787. View